Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
暂无分享,去创建一个
[1] A. Neugut,et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Balducci. Guidelines for the management of the older cancer patient. , 2005, Cancer treatment and research.
[3] A. Gambardella,et al. Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma , 2005, Cancer.
[4] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[5] Robert Livingston,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.
[6] C. Presant,et al. Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module , 2005, Cancer.
[7] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[8] H. Cohen,et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. , 2005, JAMA.
[9] S. Schraub,et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. L. Broccoli,et al. Validation of the Distress Thermometer: A single item screen to detect clinically significant psychological distress in ambulatory oncology patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Gelmon,et al. An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Schilsky,et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Cha,et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Kato,et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.
[15] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[16] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Cohen,et al. Barriers to clinical trial participation by older women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Zaslavsky,et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Cohen,et al. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. , 2003, The American journal of medicine.
[21] B. Vellas,et al. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. , 2002, Clinics in geriatric medicine.
[22] E. Lamont,et al. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Winer,et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Christian,et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Christianna S. Williams,et al. Development and Validation of a Risk‐Adjustment Index for Older Patients: The High‐Risk Diagnoses for the Elderly Scale , 2002, Journal of the American Geriatrics Society.
[26] C. Lynch,et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Shekelle,et al. The Vulnerable Elders Survey: A Tool for Identifying Vulnerable Older People in the Community , 2001, Journal of the American Geriatrics Society.
[28] A. Naeim,et al. Geriatric syndromes and assessment in older cancer patients. , 2001, Oncology.
[29] R. Labianca,et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[30] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[31] C. Begg,et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.
[32] L. Fried,et al. Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[33] R Yancik,et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.
[34] J. Armitage,et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Extermann,et al. Measurement and impact of comorbidity in older cancer patients. , 2000, Critical reviews in oncology/hematology.
[36] F. Cavalli,et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Lyman,et al. What threshold for adjuvant therapy in older breast cancer patients? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[39] A. Norman,et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] R. Havlik,et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients , 1998, Cancer.
[41] P. Ravdin,et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Swain,et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H. Muss,et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] W. Satariano,et al. The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer , 1994, Annals of Internal Medicine.
[45] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Sati Mazumdar,et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.
[47] L. Balducci,et al. Recombinant Hemopoietic Growth Factors: Comparative Hemopoietic Response in Younger and Older Subjects , 1992, Journal of the American Geriatrics Society.
[48] A. Rademaker,et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Diane Podsiadlo,et al. The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.
[50] W. Gregory,et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.
[51] M. Tinetti,et al. A simple procedure for general screening for functional disability in elderly patients. , 1990, Annals of internal medicine.
[52] R. Gelman,et al. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[54] W. Haley,et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. , 2004, Critical reviews in oncology/hematology.
[55] W. Scheithauer,et al. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). , 2004, Journal of Clinical Oncology.
[56] Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] N. Petrelli,et al. Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.
[58] E. Trimble,et al. Representation of older patients in cancer treatment trials. , 1994, Cancer.
[59] M P Lawton,et al. Scales to measure competence in everyday activities. , 1988, Psychopharmacology bulletin.
[60] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.